Is Cidara Therapeutics Inc (CDTX) undervalued? · rev $1.3M
Cidara Therapeutics Inc (CDTX) is a biotechnology company listed on US.
This page asks whether Cidara Therapeutics Inc (CDTX) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported CDTX revenue for 2024-12-31 was $1.3M. Net income was -$169.8M. Revenue was down 94.5% from 2023-12-31 to 2024-12-31. CDTX currently screens at market cap $6.96B.
CDTX currently screens at market cap $6.96B. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new CDTX 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare CDTX to the stock page model before you treat a low multiple as a gift.
Not investment advice.